Melinta is only one of several companies experiencing the pain of antibiotic development. The company lost 85% of its market cap over the past year. Yet, the company just received European approval to market Vabomere, a combination of one antibiotic, meropenem, and one beta-lactamase inhibitor vaborbactam. This is becoming a repetitive pattern of success breeding failure in the antibiotic space. Dr. David Shlaes explains.
Melinta is only one of several companies experiencing the pain of antibiotic development. The company lost 85% of its market cap over the past year. Yet, the company just received European approval to market Vabomere, a combination of one antibiotic, meropenem, and one beta-lactamase inhibitor vaborbactam. This is becoming a repetitive pattern of success breeding failure in the antibiotic space. Dr. David Shlaes explains.